The pharmacological difference between durvalumab (durvalumab) and whether it is a PD-1 or PD-L1 inhibitor

Durvalumab (Durvalumab) is aPD-L1 inhibitor and is not a PD-1 inhibitor. It is a humanized IgG1κ-type monoclonal antibody that specifically targets programmed death ligand 1 (PD-L1), by blocking PD-L1 span>binds with its receptors PD-1 and CD80 to relieve the immune suppression of T cells, thereby restoring the body's immune recognition and killing capabilities against tumor cells.

PD-1 (programmed death protein 1) inhibitors and PD-L1 inhibitors are the main The pharmacological difference lies in the different target locations: PD-1 inhibitors such as nivolumab (Nivolumab) and pembrolizumab (Nivolumab span>Pembrolizumab) directly acts on TPD-1< on the surface of T cells span> receptor, while PD-L1 inhibitors such as durvalumab act on PD-L1 molecules on the surface of tumor cells or antigen-presenting cells. Although both ultimately activate TT cellular immune function by "releasing the brakes," the blocking mechanisms are slightly different.

In clinical practice, PD-L1 inhibitors usually only block PD-L1 and PD-1/CD80 does not affect the interaction between PD-L2 and PD-1, so in theory it may have lower immune-related side effects when regulating immunity. But this does not mean that the efficacy is better. The indications, efficacy and side effects of the drug are affected by many factors and need to be supported by clinical trial data.

Durvalumab has been approved for the treatment of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and bladder cancer, it is listed as part of the first-line or maintenance treatment regimen in guidelines in many countries. As a PD-L1 inhibitor, it occupies an important position in the layout of immunotherapy, providing new treatment options for patients with advanced tumors.

Reference materials:https://www.imfinzi.com/